Literature DB >> 19212133

Challenges in the determination of early predictors of cerebral malaria: lessons from the human disease and the experimental murine models.

Yuri Chaves Martins1, Leonardo José de Moura Carvalho, Cláudio Tadeu Daniel-Ribeiro.   

Abstract

Cerebral malaria (CM) is a life-threatening complication of malaria caused by Plasmodium falciparum, and it claims around two million lives a year, mainly those of children in sub-Saharan Africa. A number of works, particularly in murine models of CM, showed that several mediators are involved in the development of the disease, including monocytes, T lymphocytes, cytokines, chemokines, platelets, nitric oxide scavengers and heme, among others, but a comprehensive understanding of the pathogenesis of this complication is still lacking. This overview critically analyzes and discusses the definition, clinical features, neurocognitive outcomes and pathogenesis of human CM. We focused on the relationship between clinical and laboratory features and the diagnosis and prognosis of the complication showing indicators of poor prognosis and emphasizing the need of establishing predictive scores to estimate, on admission, the likelihood of any malarial patient to develop neurological complications. The potential development of a mathematical model for early prediction of CM through neurological assessment using the SHIRPA protocol in Plasmodium berghei ANKA-infected susceptible mice is shown. High positive predictive values (>89%) on days 5 and 6 of infection, observed for some generated SHIRPA scores, indicate the possibility of early detection of mice with a high probability of developing CM. Copyright (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19212133     DOI: 10.1159/000180268

Source DB:  PubMed          Journal:  Neuroimmunomodulation        ISSN: 1021-7401            Impact factor:   2.492


  15 in total

1.  Perillyl alcohol reduces parasite sequestration and cerebrovascular dysfunction during experimental cerebral malaria.

Authors:  Adriana A Marin; Oscar Murillo; Rodrigo A Sussmann; Luana S Ortolan; Daniella S Battagello; Thatyane de Castro Quirino; Jackson C Bittencourt; Sabrina Epiphanio; Alejandro M Katzin; Leonardo J M Carvalho
Journal:  Antimicrob Agents Chemother       Date:  2021-03-01       Impact factor: 5.191

2.  VP-shunt dysfunction caused by malaria CNS infection.

Authors:  Michael Karl Fehrenbach; Matthias Bernhard; Manuela Siekmeyer; Norman Lippmann; Wieland Kiess; Ulf Nestler; Jürgen Meixensberger; Matthias Preuss
Journal:  Childs Nerv Syst       Date:  2015-09-22       Impact factor: 1.475

3.  Endothelin-1 Treatment Induces an Experimental Cerebral Malaria-Like Syndrome in C57BL/6 Mice Infected with Plasmodium berghei NK65.

Authors:  Yuri C Martins; Brandi D Freeman; Oscar B Akide Ndunge; Louis M Weiss; Herbert B Tanowitz; Mahalia S Desruisseaux
Journal:  Am J Pathol       Date:  2016-09-15       Impact factor: 4.307

4.  Role of the aryl hydrocarbon receptor in the immune response profile and development of pathology during Plasmodium berghei Anka infection.

Authors:  Fatima Brant; Aline S Miranda; Lisia Esper; David Henrique Rodrigues; Lucas Miranda Kangussu; Daniella Bonaventura; Frederico Marianetti Soriani; Vanessa Pinho; Danielle G Souza; Milene Alvarenga Rachid; Louis M Weiss; Herbert B Tanowitz; Mauro Martins Teixeira; Antônio Lucio Teixeira; Fabiana Simão Machado
Journal:  Infect Immun       Date:  2014-05-12       Impact factor: 3.441

5.  Cognitive dysfunction is sustained after rescue therapy in experimental cerebral malaria, and is reduced by additive antioxidant therapy.

Authors:  Patricia A Reis; Clarissa M Comim; Fernanda Hermani; Bruno Silva; Tatiana Barichello; Aline C Portella; Flavia C A Gomes; Ive M Sab; Valber S Frutuoso; Marcus F Oliveira; Patricia T Bozza; Fernando A Bozza; Felipe Dal-Pizzol; Guy A Zimmerman; João Quevedo; Hugo C Castro-Faria-Neto
Journal:  PLoS Pathog       Date:  2010-06-24       Impact factor: 6.823

6.  A new hypothesis on the manifestation of cerebral malaria: the secret is in the liver.

Authors:  Yuri Chaves Martins; Cláudio Tadeu Daniel-Ribeiro
Journal:  Med Hypotheses       Date:  2013-08-13       Impact factor: 1.538

7.  Atorvastatin treatment is effective when used in combination with mefloquine in an experimental cerebral malaria murine model.

Authors:  Jean-Baptiste Souraud; Sébastien Briolant; Jérome Dormoi; Joel Mosnier; Hélène Savini; Eric Baret; Rémy Amalvict; Raoulin Soulard; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2012-01-10       Impact factor: 2.979

8.  Erythropoietin treatment alleviates ultrastructural myelin changes induced by murine cerebral malaria.

Authors:  Casper Hempel; Poul Hyttel; Trine Staalsø; Jens R Nyengaard; Jørgen A L Kurtzhals
Journal:  Malar J       Date:  2012-06-28       Impact factor: 2.979

9.  Slow and continuous delivery of a low dose of nimodipine improves survival and electrocardiogram parameters in rescue therapy of mice with experimental cerebral malaria.

Authors:  Yuri C Martins; Leah Clemmer; Pamela Orjuela-Sánchez; Graziela M Zanini; Peng Kai Ong; John A Frangos; Leonardo J M Carvalho
Journal:  Malar J       Date:  2013-04-24       Impact factor: 2.979

10.  Improvement of the efficacy of dihydroartemisinin with atorvastatin in an experimental cerebral malaria murine model.

Authors:  Jérôme Dormoi; Sébastien Briolant; Aurélie Pascual; Camille Desgrouas; Christelle Travaillé; Bruno Pradines
Journal:  Malar J       Date:  2013-08-30       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.